出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2021年11月
肝炎検査/診断市場; 疾患の種類（B型肝炎、C型肝炎、その他の肝炎）、テクノロジー（ELISA、RDT、PCR、INAAT）、エンドユーザー（病院、診断研究所、血液銀行）、地域別 – 2026年までの世界予測
Hepatitis Testing/Diagnosis Market by Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), Technology (ELISA, RDT, PCR, INAAT), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Region – Global Forecast to 2026
| ページ数 | 175 |
| 図表数 | 204 |
| 種別 | 英文調査報告書 |
| 価格 |
The global hepatitis testing market is projected to reach USD 3.6 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 4.7% during the forecast period. The growth of the global hepatitis testing market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis. High cost of nucleic acid tests, lack of mandates for nucleic acid tests in developing countries and unfavorable reimbursement scenarios are expected to restrain hepatitis market growth. Emerging markets, rising technological advancements in molecular diagnostics, and growth in the biotechnology and biopharmaceutical industries are expected to offer strong growth opportunities for players in the market. In contrast, changing regulatory landscape, opertationsla barriers and shortage of skilled professionals may challenge market growth to a certain extent. The hepatitis testing market is segmented based on disease type, technology, end user, and region.
“Hepatitis B segment is expected to dominate the market during the forecast period.”
Based on disease type, the hepatitis testing market is segmented into hepatitis B, hepatitis C, and other hepatitis diseases (hepatitis A, D, and E). The hepatitis B segment accounted for the largest share of the hepatitis testing market in 2020. Factors such as the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of nucleic acid tests for HBV diagnosis are driving the growth of this market segment.
“ELISA segment holds highest market share during the forecast period.”
Based on technology, the hepatitis testing market is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), and other technologies (such as sequencing, mass spectrometry, and western blotting). The ELISA segment accounted for the largest share of the hepatitis testing market in 2020. The large share of this segment can primarily be attributed to the wide acceptance of this test in clinical practices to diagnose hepatitis.
“Hospital & Diagnostic Laboratories segment to dominate the market during the forecast period.”
Based on end user, the hepatitis testing market is segmented into hospital & diagnostic laboratories, blood banks, and other end users (academic & government research institutes, nursing homes, and home care settings). In 2020, the hospital & diagnostic laboratories segment accounted for the largest share of the hepatitis testing market. The large share of this segment can be attributed to the large number of hepatitis diagnostic tests carried out in hospitals.
“North America will dominate the market during the forecast period.”
The global hepatitis testing market is segmented into North America (the US and Canada), Europe (Germany, the UK, and the Rest of Europe), Asia Pacific, and Rest of the World. In 2020, North America dominates the global market, and this trend is expected to continue during the forecast period. The large share and high growth of this region can be attributed to the rising prevalence of hepatitis and increased research and clinical trials for hepatitis testing in the US.
The primary interviews conducted for this report can be categorized as follows:
•By Company Type -Tier 1: 32%,Tier 2: 42% and Tier 26%
•By Designation – C-level:23%, D-level:35%, and Others:42%
•By Region – North America:39%, Europe:25%, Asia Pacific:26%, and Rest of the World: 10%
List of Companies Profiled in the Report
•F. Hoffmann-La Roche Ltd. (Switzerland)
•Abbott Laboratories (US)
•Siemens Healthineers AG (Germany)
•Bio-Rad Laboratories, Inc. (US)
•Danaher Corporation (US)
•QIAGEN (Netherlands)
•bioMérieux SA (France)
•DiaSorin S.P.A. (Italy)
•Ortho Clinical Diagnostics (US)
•MedMira Inc. (Canada)
•Fujirebio US, Inc. (Japan)
•Grifols, S.A. (Spain)
•Orasure Technologies (US)
•GenMark Diagnostics Inc. (US)
•Vela Diagnostics (Singapore)
•Epitope Diagnostics (US)
•Trivitron Healthcare (India)
•Meril Life Sciences Pvt. Ltd. (India)
•geneOmbio Technologies Pvt. Ltd. (India)
•Molbio Diagnostics Pvt. Ltd. (India)
Research Coverage:
This report provides a detailed picture of the global hepatitis testing market. It aims at estimating the size and future growth potential of the market across different segments, such as disease type, technology, end user and region. The report also analyzes factors (such as drivers, restraints,opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total hepatitis testing market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
•Market Penetration: Comprehensive information on hepatitis testing offered by the top 20 players in the hepatitis testing market. The report analyses the hepatitis testing market by disease type, technology, end user and region.
•Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various hepatitis testing across key geographic regions.
•Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the hepatitis testing market.
•Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the hepatitis testing market.
目次
1INTRODUCTION25
1.1OBJECTIVES OF THE STUDY25
1.2MARKET DEFINITION25
1.2.1INCLUSIONS & EXCLUSIONS OF THE STUDY25
1.3MARKET SCOPE26
FIGURE 1HEPATITIS TESTING MARKET SEGMENTATION26
1.3.1YEARS CONSIDERED FOR THE STUDY26
1.4CURRENCY27
1.5STAKEHOLDERS27
1.6SUMMARY OF CHANGES28
2RESEARCH METHODOLOGY29
2.1RESEARCH DATA29
FIGURE 2RESEARCH DESIGN29
2.1.1SECONDARY DATA30
2.1.1.1Secondary sources30
2.1.2PRIMARY DATA31
FIGURE 3PRIMARY SOURCES32
2.1.2.1Key industry insights33
FIGURE 4BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION33
2.2MARKET SIZE ESTIMATION34
FIGURE 5MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH34
2.2.1GROWTH FORECAST35
FIGURE 6CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS35
FIGURE 7TOP-DOWN APPROACH36
2.3MARKET BREAKDOWN AND DATA TRIANGULATION36
FIGURE 8DATA TRIANGULATION METHODOLOGY37
2.4MARKET SHARE ANALYSIS37
2.5ASSUMPTIONS FOR THE STUDY37
2.5.1COVID-19-SPECIFIC ASSUMPTIONS38
2.6LIMITATIONS38
2.7RISK ASSESSMENT39
2.8COVID-19 ECONOMIC ASSESSMENT39
2.9ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO39
FIGURE 9CRITERIA IMPACTING THE GLOBAL ECONOMY40
FIGURE 10RECOVERY SCENARIO OF THE GLOBAL ECONOMY41
3EXECUTIVE SUMMARY42
FIGURE 11HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021 VS. 2026 (USD MILLION)42
FIGURE 12HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION)43
FIGURE 13HEPATITIS TESTING MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)43
FIGURE 14HEPATITIS TESTING MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)44
4PREMIUM INSIGHTS45
4.1HEPATITIS TESTING MARKET OVERVIEW45
FIGURE 15HIGH BURDEN OF HEPATITIS TO DRIVE MARKET GROWTH45
4.2HEPATITIS TESTING MARKET, BY TECHNOLOGY (2021–2026)45
FIGURE 16RAPID DIAGNOSTIC TESTS SEGMENT TO REGISTER THE HIGHEST
CAGR DURING THE FORECAST PERIOD45
4.3NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE AND COUNTRY (2020)46
FIGURE 17THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH
AMERICAN HEPATITIS TESTING MARKET IN 202046
4.4HEPATITIS TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES47
FIGURE 18ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH DURING
THE FORECAST PERIOD47
5MARKET OVERVIEW48
5.1INTRODUCTION48
FIGURE 19HEPATITIS TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES48
5.2MARKET DYNAMICS48
5.2.1DRIVERS48
5.2.1.1High burden of hepatitis48
TABLE 1HEPATITIS PREVALENCE, BY REGION, 2019 (MILLION)49
5.2.1.2Increasing blood transfusion and donations49
TABLE 2AVERAGE PREVALENCE OF HEPATITIS INFECTION IN BLOOD DONATIONS,
BY INCOME GROUP50
5.2.1.3Benefits of POC instruments and kits50
5.2.1.4Awareness initiatives on hepatitis50
5.2.2RESTRAINTS51
5.2.2.1High cost of nucleic acid tests51
5.2.2.2Lack of mandates for nucleic acid tests in developing countries51
5.2.2.3Unfavorable reimbursement scenario51
5.2.3OPPORTUNITIES51
5.2.3.1Emerging markets51
5.2.3.2Rising technological advancements in molecular diagnostics52
5.2.3.3Growth in the biotechnology and biopharmaceutical industries52
5.2.4CHALLENGES52
5.2.4.1Changing regulatory landscape52
5.2.4.2Operational barriers53
5.2.4.3Shortage of skilled professionals53
5.3COVID-19 IMPACT ON THE HEPATITIS TESTING MARKET53
6HEPATITIS TESTING MARKET, BY DISEASE TYPE55
6.1INTRODUCTION56
TABLE 3HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)56
TABLE 4HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)56
6.2HEPATITIS B (HBV)56
6.2.1HEPATITIS B SEGMENT TO HOLD THE LARGEST MARKET SHARE DURING
THE FORECAST PERIOD56
TABLE 5HEPATITIS B CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 201957
TABLE 6HEPATITIS B TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)57
TABLE 7HEPATITIS B TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)57
TABLE 8NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION)58
TABLE 9NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION)58
TABLE 10EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION)58
TABLE 11EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION)59
6.3HEPATITIS C (HCV)59
6.3.1GOVERNMENT INITIATIVES FOR SUPPORTING HCV DIAGNOSIS
TO DRIVE MARKET GROWTH59
TABLE 12HEPATITIS C CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 201959
TABLE 13HEPATITIS C TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)60
TABLE 14HEPATITIS C TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)60
TABLE 15NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION)60
TABLE 16NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION)61
TABLE 17EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION)61
TABLE 18EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION)61
6.4OTHER HEPATITIS DISEASES62
TABLE 19REP0RTED HEPATITIS A CASES IN THE US SINCE 201662
TABLE 20OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION,
2018–2020 (USD MILLION)62
TABLE 21OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION,
2021–2026 (USD MILLION)63
TABLE 22NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET,
BY COUNTRY, 2018–2020 (USD MILLION)63
TABLE 23NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET,
BY COUNTRY, 2021–2026 (USD MILLION)63
TABLE 24EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION)64
TABLE 25EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION)64
7HEPATITIS TESTING MARKET, BY TECHNOLOGY65
7.1INTRODUCTION66
TABLE 26HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)66
TABLE 27HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)66
7.2ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)67
7.2.1ELISA IS WIDELY USED FOR THE DETECTION OF HEPATITIS67
TABLE 28HEPATITIS TESTING MARKET FOR ELISA, BY REGION,
2018–2020 (USD MILLION)67
TABLE 29HEPATITIS TESTING MARKET FOR ELISA, BY REGION,
2021–2026 (USD MILLION)68
TABLE 30NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2018–2020 (USD MILLION)68
TABLE 31NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2021–2026 (USD MILLION)68
TABLE 32EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY,
2018–2020 (USD MILLION)69
TABLE 33EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY,
2021–2026 (USD MILLION)69
7.3RAPID DIAGNOSTIC TESTS (RDT)69
7.3.1RAPID TESTS ARE HIGHLY USEFUL IN COUNTRIES WITH LIMITED ACCESSIBILITY TO SOPHISTICATED TECHNOLOGIES69
TABLE 34HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2018–2020 (USD MILLION)70
TABLE 35HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2021–2026 (USD MILLION)70
TABLE 36NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018–2020 (USD MILLION)71
TABLE 37NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2021–2026 (USD MILLION)71
TABLE 38EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS,
BY COUNTRY, 2018–2020 (USD MILLION)71
TABLE 39EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS,
BY COUNTRY, 2021–2026 (USD MILLION)72
7.4POLYMERASE CHAIN REACTION (PCR)72
7.4.1PCR TECHNOLOGY IS USED IN CONFIRMATORY TESTS FOR
HEPATITIS DIAGNOSIS72
TABLE 40HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2018–2020 (USD MILLION)72
TABLE 41HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2021–2026 (USD MILLION)73
TABLE 42NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2020 (USD MILLION)73
TABLE 43NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION)73
TABLE 44EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2020 (USD MILLION)74
TABLE 45EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION)74
7.5ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)74
7.5.1COST-BENEFITS OF INAAT ARE DRIVING THE GROWTH OF THIS MARKET SEGMENT74
TABLE 46HEPATITIS TESTING MARKET FOR INAAT, BY REGION,
2018–2020 (USD MILLION)75
TABLE 47HEPATITIS TESTING MARKET FOR INAAT, BY REGION,
2021–2026 (USD MILLION)75
TABLE 48NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2018–2020 (USD MILLION)75
TABLE 49NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2021–2026 (USD MILLION)76
TABLE 50EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY,
2018–2020 (USD MILLION)76
TABLE 51EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY,
2021–2026 (USD MILLION)76
7.6OTHER TECHNOLOGIES77
TABLE 52HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2018–2020 (USD MILLION)77
TABLE 53HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2021–2026 (USD MILLION)77
TABLE 54NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2020 (USD MILLION)78
TABLE 55NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION)78
TABLE 56EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2018–2020 (USD MILLION)78
TABLE 57EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2021–2026 (USD MILLION)79
8HEPATITIS TESTING MARKET, BY END USER80
8.1INTRODUCTION81
TABLE 58HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)81
TABLE 59HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)81
8.2HOSPITAL & DIAGNOSTIC LABORATORIES81
8.2.1HOSPITAL & DIAGNOSTIC LABORATORIES ARE THE LARGEST END USERS
OF HEPATITIS TESTING PRODUCTS81
TABLE 60HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018–2020 (USD MILLION)82
TABLE 61HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2021–2026 (USD MILLION)83
TABLE 62NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2020 (USD MILLION)83
TABLE 63NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION)83
TABLE 64EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2020 (USD MILLION)84
TABLE 65EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION)84
8.3BLOOD BANKS84
8.3.1INCREASING NUMBER OF BLOOD DONATIONS TO DRIVE THE GROWTH
OF THIS MARKET SEGMENT84
TABLE 66HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION,
2018–2020 (USD MILLION)85
TABLE 67HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION,
2021–2026 (USD MILLION)85
TABLE 68NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS,
BY COUNTRY, 2018–2020 (USD MILLION)85
TABLE 69NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS,
BY COUNTRY, 2021–2026 (USD MILLION)86
TABLE 70EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2018–2020 (USD MILLION)86
TABLE 71EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2026 (USD MILLION)86
8.4OTHER END USERS87
TABLE 72HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION,
2018–2020 (USD MILLION)87
TABLE 73HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION,
2021–2026 (USD MILLION)87
TABLE 74NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2020 (USD MILLION)87
TABLE 75NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2021–2026 (USD MILLION)88
TABLE 76EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2020 (USD MILLION)88
TABLE 77EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION)88
9EPATITIS TESTING MARKET, BY REGION89
9.1INTRODUCTION90
TABLE 78GLOBAL: HEPATITIS TESTING MARKET, BY REGION,
2018–2020 (USD MILLION)90
TABLE 79GLOBAL: HEPATITIS TESTING MARKET, BY REGION,
2021–2026 (USD MILLION)90
9.2NORTH AMERICA90
FIGURE 20NORTH AMERICA: HEPATITIS TESTING MARKET SNAPSHOT91
TABLE 80NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION)91
TABLE 81NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION)92
TABLE 82NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)92
TABLE 83NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)92
TABLE 84NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)93
TABLE 85NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)93
TABLE 86NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION)93
TABLE 87NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION)94
9.2.1US94
9.2.1.1High healthcare expenditure to drive market growth in the US94
TABLE 88US: NUMBER OF HEPATITIS A CASES REPORTED, 2015 VS. 201994
TABLE 89HEPATITIS A PREVALENCE RATE PER 100,000 POPULATION
IN THE US, 2013–201795
TABLE 90US: KEY MACROINDICATORS95
TABLE 91US: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)96
TABLE 92US: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)96
TABLE 93US: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)96
TABLE 94US: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)97
TABLE 95US: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)97
TABLE 96US: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)97
9.2.2CANADA98
9.2.2.1Favorable government initiatives are expected to boost market growth in Canada98
TABLE 97CANADA: KEY MACROINDICATORS98
TABLE 98CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)99
TABLE 99CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)99
TABLE 100CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)99
TABLE 101CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)100
TABLE 102CANADA: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION)100
TABLE 103CANADA: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION)100
9.3EUROPE101
TABLE 104NUMBER OF HEPATITIS B CASES IN EUROPE, BY COUNTRY, 2014–2018101
TABLE 105EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION)101
TABLE 106EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION)102
TABLE 107EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)102
TABLE 108EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)102
TABLE 109EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)103
TABLE 110EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)103
TABLE 111EUROPE: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION)103
TABLE 112EUROPE: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION)104
9.3.1GERMANY104
9.3.1.1Increasing demand for advanced diagnostic technologies to drive market growth in Germany104
TABLE 113GERMANY: KEY MACROINDICATORS104
TABLE 114GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)105
TABLE 115GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)105
TABLE 116GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)105
TABLE 117GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)106
TABLE 118GERMANY: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION)106
TABLE 119GERMANY: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION)106
9.3.2UK107
9.3.2.1Increasing number of clinical laboratories to drive market
growth in the UK107
TABLE 120NUMBER OF HEPATITIS C CASES REPORTED IN ENGLAND AND
WALES, 2008–2018107
TABLE 121UK: KEY MACROINDICATORS108
TABLE 122UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)108
TABLE 123UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)108
TABLE 124UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)109
TABLE 125UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)109
TABLE 126UK: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)109
TABLE 127UK: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)110
9.3.3REST OF EUROPE110
TABLE 128ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP)111
TABLE 129ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)112
TABLE 130ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)112
TABLE 131ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)112
TABLE 132ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)113
TABLE 133ROE: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION)113
TABLE 134ROE: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION)113
9.4ASIA PACIFIC114
9.4.1HIGH PREVALENCE OF HEPATITIS TO BOOST MARKET GROWTH114
TABLE 135ASIA PACIFIC: ESTIMATED PREVALENCE OF CHRONIC HBV AND HCV114
TABLE 136ASIA PACIFIC: COST COVERAGE FOR THE DIAGNOSIS OF CHRONIC
VIRAL HEPATITIS114
FIGURE 21ASIA PACIFIC: HEPATITIS TESTING MARKET SNAPSHOT115
TABLE 137CHINA: KEY MACROINDICATORS116
TABLE 138JAPAN: KEY MACROINDICATORS116
TABLE 139INDIA: KEY MACROINDICATORS117
TABLE 140ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)117
TABLE 141ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)118
TABLE 142ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)118
TABLE 143ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)118
TABLE 144ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION)119
TABLE 145ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION)119
9.5REST OF THE WORLD119
9.5.1LESS-STRINGENT REGULATIONS FOR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH119
TABLE 146REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)120
TABLE 147REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)121
TABLE 148REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)121
TABLE 149REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)121
TABLE 150REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION)122
TABLE 151REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION)122
10COMPETITIVE LANDSCAPE123
10.1OVERVIEW123
10.2KEY PLAYER STRATEGIES/RIGHT TO WIN123
TABLE 152OVERVIEW OF STRATEGIES ADOPTED BY KEY HEPATITIS TESTING
MARKET PLAYERS123
10.3MARKET SHARE ANALYSIS124
FIGURE 22HEPATITIS TESTING MARKET SHARE ANALYSIS, 2020124
TABLE 153HEPATITIS TESTING MARKET: DEGREE OF COMPETITION (2020)125
10.4COMPANY EVALUATION QUADRANT126
10.4.1STARS126
10.4.2EMERGING LEADERS126
10.4.3PERVASIVE PLAYERS126
10.4.4PARTICIPANTS126
FIGURE 23HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT (2020)127
10.5COMPANY EVALUATION QUADRANT: SMES/START-UPS127
10.5.1PROGRESSIVE COMPANIES127
10.5.2STARTING BLOCKS128
10.5.3RESPONSIVE COMPANIES128
10.5.4DYNAMIC COMPANIES128
FIGURE 24HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT
FOR SMES & START-UPS (2020)128
10.6COMPETITIVE SCENARIO129
10.6.1PRODUCT LAUNCHES & APPROVALS129
TABLE 154PRODUCT LAUNCHES & APPROVALS129
10.6.2DEALS130
TABLE 155DEALS130
10.6.3OTHER DEVELOPMENTS130
TABLE 156OTHER DEVELOPMENTS130
10.7COMPANY FOOTPRINT ANALYSIS131
TABLE 157TECHNOLOGY, DISEASE TYPE, AND REGIONAL FOOTPRINT OF COMPANIES131
TABLE 158TECHNOLOGY FOOTPRINT OF COMPANIES132
TABLE 159DISEASE TYPE FOOTPRINT OF COMPANIES133
TABLE 160REGIONAL FOOTPRINT OF COMPANIES134
11COMPANY PROFILE135
11.1KEY PLAYERS135
(Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats)*
11.1.1ABBOTT LABORATORIES135
TABLE 161ABBOTT LABORATORIES: BUSINESS OVERVIEW135
FIGURE 25ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)136
11.1.2F. HOFFMANN-LA ROCHE LTD.139
TABLE 162F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW139
FIGURE 26F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)140
11.1.3BIO-RAD LABORATORIES, INC.143
TABLE 163BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW143
FIGURE 27BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)144
11.1.4SIEMENS HEALTHINEERS AG146
TABLE 164SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW146
FIGURE 28SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2020)147
11.1.5DIASORIN S.P.A149
TABLE 165DIASORIN S.P.A: BUSINESS OVERVIEW149
FIGURE 29DIASORIN S.P.A.: COMPANY SNAPSHOT (2020)150
11.1.6QIAGEN153
TABLE 166QIAGEN: BUSINESS OVERVIEW153
FIGURE 30QIAGEN: COMPANY SNAPSHOT (2020)154
11.1.7DANAHER CORPORATION155
TABLE 167DANAHER CORPORATION: BUSINESS OVERVIEW155
FIGURE 31DANAHER CORPORATION: COMPANY SNAPSHOT (2020)156
11.1.8GRIFOLS, S.A.158
TABLE 168GRIFOLS, S.A.: BUSINESS OVERVIEW158
FIGURE 32GRIFOLS, S.A.: COMPANY SNAPSHOT (2020)159
11.1.9BIOMÉRIEUX SA160
TABLE 169BIOMÉRIEUX SA: BUSINESS OVERVIEW160
FIGURE 33BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)161
11.1.10ORTHO CLINICAL DIAGNOSTICS162
TABLE 170ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW162
FIGURE 34ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020)163
11.2OTHER PLAYERS164
11.2.1FUJIREBIO US, INC.164
11.2.2ORASURE TECHNOLOGIES165
11.2.3EPITOPE DIAGNOSTICS166
11.2.4TRIVITRON HEALTHCARE167
11.2.5MERIL LIFE SCIENCES PVT. LTD.168
11.2.6GENMARK DIAGNOSTICS INC.169
11.2.7VELA DIAGNOSTICS170
11.2.8MOLBIO DIAGNOSTICS PVT. LTD.171
11.2.9GENEOMBIO TECHNOLOGIES PVT. LTD.172
11.2.10MEDMIRA INC.173
*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats might not be captured in case of unlisted companies.
12APPENDIX174
12.1INSIGHTS FROM INDUSTRY EXPERTS174
12.2DISCUSSION GUIDE175
12.3KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL178
12.4AVAILABLE CUSTOMIZATIONS180
12.5RELATED REPORTS180
12.6AUTHOR DETAILS181
お問合せフォーム